Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Inclusion criteria

• ✓. Patients must provide written informed consent prior to any screening procedures.
• ✓. Age 18 years or older.
• ✓. Willing and able to comply with scheduled visits, treatment plan and laboratory tests
• ✓. Must have WHO Grade IV Glioblastoma or gliosarcoma based on histopathological OR molecular criteria
• ✓. Patients tumor target (GTV) should be ≤ 5 cm.
• ✓. a) Must have received first-line multimodal therapy with surgery (resection or biopsy) followed by radiation and Temozolomide (unless known MGMT promoter unmethylated) AND b) Must have completed at least 21 days of combination and Temozolomide therapy (unless known MGMT promoter unmethylated. . An interval of at least 12 weeks after the end of combination radiation therapy + Temozolomide is required unless there is: i.) Histopathologic confirmation of recurrent tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field. (\*NOTE: Patients treated with Optune device or who received Gliadel wafers placed during the first surgery are eligible.
• ✓. Must have no more than 2 recurrences of either GBM or gliosarcoma. Recurrence must be confirmed by diagnostic biopsy/surgery with local pathology review OR contrast-enhanced MRI measurable by RANO criteria. (\*NOTE: Patients diagnosed with WHO Grade III that undergo surgical resection and are found to have WHO Grade IV or gliosarcoma are considered eligible).